PROCEPT BioRobotics (PRCT) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for PROCEPT BioRobotics (NASDAQ: PRCT):

• 11/7/2026 – PROCEPT BioRobotics was upgraded by Wall Street Zen from “sell” to “hold”.
• 11/6/2026 – PROCEPT BioRobotics had its price target raised by Truist Financial from $21.00 to $24.00. They now have a “hold” rating on the stock.
• 11/5/2026 – PROCEPT BioRobotics had its price target raised by UBS Group from $20.00 to $21.00. They now have a “neutral” rating on the stock.
• 11/5/2026 – PROCEPT BioRobotics had its price target raised by Leerink Partners from $20.00 to $22.00. They now have a “market perform” rating on the stock.
• 10/16/2026 – PROCEPT BioRobotics was upgraded by Piper Sandler to “strong-buy”.
• 10/15/2026 – PROCEPT BioRobotics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 10/6/2026 – PROCEPT BioRobotics is now covered by Barclays. They set an “overweight” rating and a $30.00 price target on the stock.
• 10/6/2026 – PROCEPT BioRobotics was upgraded by Barclays to “strong-buy”.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ:PRCT traded down $0.14 during trading on Wednesday, hitting $22.91. The stock had a trading volume of 317,916 shares, compared to its average volume of 1,508,084. PROCEPT BioRobotics Corporation has a 12-month low of $16.67 and a 12-month high of $38.11. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -11.34 and a beta of 0.88. The company has a quick ratio of 4.73, a current ratio of 5.89 and a debt-to-equity ratio of 0.16. The stock has a 50-day simple moving average of $19.39 and a two-hundred day simple moving average of $23.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative net margin of 32.60% and a negative return on equity of 33.23%. The company had revenue of $98.29 million during the quarter, compared to analyst estimates of $100.52 million. During the same period last year, the firm earned ($0.38) EPS. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.74 earnings per share for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In related news, insider Pooja Sharma sold 4,710 shares of the business’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $19.71, for a total value of $92,834.10. Following the sale, the insider owned 106,471 shares in the company, valued at approximately $2,098,543.41. The trade was a 4.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 5,753 shares of company stock valued at $114,685. Corporate insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics develops and commercializes surgical robotic systems for urology, with a focus on treating benign prostatic hyperplasia, or BPH, an enlargement of the prostate that can cause urinary symptoms. The company’s core offering is Aquablation therapy, delivered using its AquaBeam Robotic System. The procedure combines imaging guidance with a surgeon-controlled, robotically assisted waterjet to remove prostate tissue. PROCEPT also offers its HYDROS Robotic System, a platform designed to deliver Aquablation therapy.